Clinical Potential of Vorapaxar in Cardiovascular Risk Reduction in Patients with Atherosclerosis

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2015 Sep 9

PMID 26346960

Citations 1

Authors

Philipp Diehl

Christoph Bode

Daniel Duerschmied

Affiliations

Soon will be listed here.

Abstract

Vorapaxar (ZONTIVITY™, formerly known as SCH 530348) is a specific, orally active antagonist of the protease-activated receptor-1 (PAR-1) on platelets. It inhibits thrombin-induced platelet activation by binding to the ectodomain of PAR-1. After animal studies and Phase II studies showed that vorapaxar sufficiently inhibits platelet activation without significantly increasing bleeding complications, safety and efficacy of vorapaxar were assessed in two large multicenter trials in patients with coronary artery disease and atherosclerosis. The Thrombin-Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndromes (TRACER) trial investigated safety and efficacy of vorapaxar in patients with an acute coronary syndrome without ST-segment elevation. The Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis In Myocardial Infarction 50 (TRA 2°P-TIMI 50) investigated atherothrombotic events in patients with stable atherosclerosis. Results of both studies suggested that vorapaxar given in addition to standard antiplatelet therapy can reduce atherothrombotic events, but increases the risk of mild and moderate bleeding complications. This review article summarizes the main results of TRACER and TRA 2°P-TIMI 50 and suggests patient cohorts that might benefit from treatment with vorapaxar in addition to standard antiplatelet therapy.

Citing Articles

Identification of a New Function of Cardiovascular Disease Drug 3-Morpholinosydnonimine Hydrochloride as an Amyloid-β Aggregation Inhibitor.

Ren B, Zhang M, Hu R, Chen H, Wang M, Lin Y ACS Omega. 2018; 2(1):243-250.

PMID: 30023514 PMC: 6044715. DOI: 10.1021/acsomega.6b00397.

References

Jones W, Tricoci P, Huang Z, Moliterno D, Harrington R, Sinnaeve P . Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). Am Heart J. 2014; 168(4):588-96. DOI: 10.1016/j.ahj.2014.06.017. View

Mega J, Braunwald E, Wiviott S, Bassand J, Bhatt D, Bode C . Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2011; 366(1):9-19. DOI: 10.1056/NEJMoa1112277. View

Mehran R, Rao S, Bhatt D, Gibson C, Caixeta A, Eikelboom J . Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011; 123(23):2736-47. DOI: 10.1161/CIRCULATIONAHA.110.009449. View

Heeschen C, Dimmeler S, Hamm C, van den Brand M, Boersma E, Zeiher A . Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003; 348(12):1104-11. DOI: 10.1056/NEJMoa022600. View

Kosoglou T, Kraft W, Kumar B, Statkevich P, Xuan F, Ma L . Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. Eur J Clin Pharmacol. 2012; 68(7):1049-56. DOI: 10.1007/s00228-012-1217-6. View

Ghosal A, Lu X, Penner N, Gao L, Ramanathan R, Chowdhury S . Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. Drug Metab Dispos. 2010; 39(1):30-8. DOI: 10.1124/dmd.110.035493. View

Morrow D, Braunwald E, Bonaca M, Ameriso S, Dalby A, Fish M . Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012; 366(15):1404-13. DOI: 10.1056/NEJMoa1200933. View

Bonaca M, Scirica B, Creager M, Olin J, Bounameaux H, Dellborg M . Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013; 127(14):1522-9, 1529e1-6. DOI: 10.1161/CIRCULATIONAHA.112.000679. View

Chackalamannil S, Wang Y, Greenlee W, Hu Z, Xia Y, Ahn H . Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008; 51(11):3061-4. DOI: 10.1021/jm800180e. View

10.

Edelstein L, Simon L, Lindsay C, Kong X, Teruel-Montoya R, Tourdot B . Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood. 2014; 124(23):3450-8. PMC: 4246040. DOI: 10.1182/blood-2014-04-572479. View

11.

Tricoci P, Huang Z, Held C, Moliterno D, Armstrong P, Van de Werf F . Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2011; 366(1):20-33. DOI: 10.1056/NEJMoa1109719. View

12.

Steg P, James S, Atar D, Badano L, Blomstrom-Lundqvist C, Borger M . ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33(20):2569-619. DOI: 10.1093/eurheartj/ehs215. View

13.

Coughlin S . Thrombin signalling and protease-activated receptors. Nature. 2000; 407(6801):258-64. DOI: 10.1038/35025229. View

14.

Coughlin S . Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005; 3(8):1800-14. DOI: 10.1111/j.1538-7836.2005.01377.x. View

15.

Jennings L . Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost. 2009; 102(2):248-57. DOI: 10.1160/TH09-03-0192. View

16.

Royle N, Irwin D, Koschinsky M, MacGillivray R, Hamerton J . Human genes encoding prothrombin and ceruloplasmin map to 11p11-q12 and 3q21-24, respectively. Somat Cell Mol Genet. 1987; 13(3):285-92. DOI: 10.1007/BF01535211. View

17.

Andersen H, Greenberg D, Fujikawa K, Xu W, Chung D, Davie E . Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci U S A. 1999; 96(20):11189-93. PMC: 18009. DOI: 10.1073/pnas.96.20.11189. View

18.

Mauri L, Hsieh W, Massaro J, Ho K, DAgostino R, Cutlip D . Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007; 356(10):1020-9. DOI: 10.1056/NEJMoa067731. View

19.

COOK J, Sitko G, Bednar B, Condra C, Mellott M, Feng D . An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation. 1995; 91(12):2961-71. DOI: 10.1161/01.cir.91.12.2961. View

20.

Becker R, Moliterno D, Jennings L, Pieper K, Pei J, Niederman A . Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009; 373(9667):919-28. DOI: 10.1016/S0140-6736(09)60230-0. View